Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intellia Therapeutics, Inc. (NTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback - On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - Plans to present additional clinical data in 2023 from the ongoing NTLA-2001 first-in-human study by year-end - Expects to submit a Clinical Trial Application by year-end for NTLA-3001, Intellia’s first in vivo inser..."
08/02/2023 4 Bhanji Muna (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Sold 265 shares @ $42.33, valued at $11.2k
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 4 Bhanji Muna (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Sold 1,867 shares @ $39.3, valued at $73.4k
07/06/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 4 Clark Eliana (EVP, Chief Technical Officer) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Sold 360 shares @ $40.51, valued at $14.6k
06/16/2023 4 CHASE WILLIAM J (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 1,673 shares @ $0
Granted 2,447 options to buy @ $45.2, valued at $110.6k
06/16/2023 4 Verwiel Frank (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 4 Keresty Georgia (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 4 GOODMAN JESSE (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 4 Crowley John F (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 4 Cohen Fred E (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 4 Bhanji Muna (Director) has filed a Form 4 on Intellia Therapeutics, Inc.
Txns: Granted 4,425 shares @ $0
Granted 6,473 options to buy @ $45.2, valued at $292.6k
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIA THERAPEUTICS, INC. Intellia Therapeutics, Inc. , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware , DOES HEREBY CERTIFY: 1. That the name of this corporation is Intellia Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on May 7, 2014 under the name AZRN, Inc. 2. That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Second Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate ..."
06/12/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Intellia Therapeutics Announces New Positive Clinical Data from Phase 1study of"
06/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. from Its Board of Directors CAMBRIDGE, Mass., June 5, 2023 — Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023. “Working with the team at Intellia and seeing the company's transformation from an idea to a leader in genome editing has been one of the most exciting journeys in my career,” said Jean-François Formela, M.D. “I am confident this is just the beginning for John and his team. I can't wait to see Intellia's next chapter and how they will transform the future..."
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress - Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023 - Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing next wave of clinical candidates, including NTLA-3001 and NTLA-2003, and advancing novel gene editing capabilities - Ended the first quarter o..."
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces FDA Clearance of Investigational New Drug"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress - Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema - Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study - Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; global pivotal study initiation anticipated by year-end 2023 - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing IND-enabling activities for two alpha-1 antitrypsin deficiency candidates, NTLA-2003 and NTLA-3001; ..."
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 11.2% stake in Intellia Therapeutics, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy